Delphi advisor to Immunicum in connection with rights issue

Advokatfirman Delphi has acted as legal advisor to Immunicum AB in connection with a rights issue of approximately SEK 200 million.

Immunicum is a biotechnology company advancing a novel immuno-oncology treatment against a range of solid tumors. The company aims to advance therapeutic cancer treatments at least through clinical phase II trials and then license the product candidates to major pharmaceutical or biotech companies.